ArticleProstate international2025
Utility of the prostate health index density for detecting clinically significant prostate cancer in patients with negative magnetic resonance imaging findings.
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Context-dependent role of digital rectal examination in a contemporary prostate biopsy cohort: differential predictive value with and without multiparametric magnetic resonance imaging.Prostate international · 2026Article
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Development and internal validation of a parsimonious logistic regression model integrating multiparametric clinical indicators for predicting prostate cancer in the PI-RADS 3 cohort.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiparametric magnetic resonance imaging (MRI) is widely used in prostate cancer diagnosis; however, a significant proportion of clinically important cancers can be missed in patients with negative MRI findings. Although attempts have been made to analyze prostate-specific antigen (PSA)-related parameters to improve the specificity of PSA testing, no evidence-based cutoff values have been established. This study aimed to evaluate the diagnostic performance of the prostate health index (PHI) and PHI density (PHID) in detecting clinically significant prostate cancer (csPCa) in the MRI-negative population. Methods: A retrospective analysis was conducted on 339 MRI-negative patients with PSA levels of 3-15 ng/mL who underwent PHI testing and MRI between September 2022 and July 2024. MRI-negative patients were defined as those with Prostate Imaging Reporting and Data System (PI-RADS) category 1 or 2 lesions. Biopsies were performed in 181 patients. The diagnostic accuracies of PSA, % free PSA, PHI, PSA density, and PHID were assessed using the receiver operating characteristic curves. Results: Among the 47 patients with PI-RADS 1 or 2 who underwent biopsy, 24 (51.1%) had prostate cancer, of whom 16 (66.7%) had csPCa. The PHID showed the highest diagnostic performance (area under the curve [AUC] = 0.8832 for any cancer; AUC = 0.7843 for csPCa). Two patients with a PHI <27.2 were diagnosed with low-risk cancer (Gleason 6). Conclusions: The PHI and PHID may serve as valuable adjuncts to MRI for the detection of csPCa and may help avoid unnecessary biopsies in patients with negative MRI findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.